Roundtable Discussion: Transforming Conjugate Chemistry into Clinically Feasible Oligonucleotide Therapies
- Discover strategies to optimise oligonucleotide-peptide or oligonucleotide antibody conjugates for reproducible, scalable GMP production
- Balancing complex conjugate chemistry with manufacturing priorities: learnings from the successes and the failures
- Evaluate sustainable and cost-effective manufacturing approaches, including enzymatic synthesis and green chemistry alternatives, to support long-term clinical development